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Abstract 
Background:  Heart failure (HF) remains a condition with high morbidity and mortality.  We 
tested a telephone support strategy to reduce major events in rural and remote Australians 
with HF, who have limited healthcare access.  Telephone support comprised an interactive 
telecommunication software tool (TeleWatch) with follow-up by trained cardiac nurses. 
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Methods:  Patients with a general practice (GP) diagnosis of HF were randomised to usual 
care (UC) or UC and telephone support intervention (UC+I) using a cluster design involving 
143 GPs throughout Australia.  Patients were followed for 12 months.  The primary end-point 
was the Packer clinical composite score. Secondary end-points included hospitalisation for 
any cause, death or hospitalisation, as well as HF hospitalisation. 
 
Results:  Four hundred and five patients were randomised into CHAT.  Patients were well 
matched at baseline for key demographic variables.  The primary end-point of the Packer 
Score was not different between the two groups (P=0.98), although more patients improved 
with UC+I.  There were fewer patients hospitalised for any cause (74 versus 114, adjusted 
HR 0.67 [95% CI 0.50-0.89], p=0.006) and who died or were hospitalised (89 versus 124, 
adjusted HR 0.70 [95% CI 0.53 – 0.92], p=0.011), in the UC+I vs UC group.  HF 
hospitalisations were reduced with UC+I (23 versus 35, adjusted HR 0.81 [95% CI 0.44 – 
1.38]), although this was not significant (p=0.43). There were 16 deaths in the UC group and 
17 in the UC+I group (p=0.43). 
 
Conclusions:  Although no difference was observed in the primary end-point of CHAT 
(Packer composite score), UC+I significantly reduced the number of HF patients hospitalised 
amongst a rural and remote cohort.  These data suggest that telephone support may be an  
efficacious approach to improve clinical outcomes in rural and remote HF patients.
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Background 
Chronic heart failure (CHF) is a major public health problem.  This condition is associated 
with reduced survival, frequent hospitalisation, poor quality of life and high healthcare costs 
[1]. 
 
Disparities exist between rural and remote areas in comparison to major metropolitan 
locations with regard to prevalence of the disease and its management.  We have previously 
shown a higher prevalence of chronic heart failure in such remote areas as well as reduced 
utilisation of diagnostic techniques such as echocardiography, less prescription of life-saving 
therapies and fewer referrals to specialists in the field [2].  Many of these issues relate to 
distances involved in accessing adequate care of such patients.  Furthermore, 
multidisciplinary and community-based care which has been shown to provide substantial 
benefit to the patient with heart failure [3-5] is unavailable in these areas.  Such models of 
care are not ideally suited to that of the rural and remote patient because of issues of access, 
with these services being located primarily in inner metropolitan areas. 
 
Thus, new strategies are required to help optimise the care of the rural and remote patient.  
Telephone support of such patients may help overcome some of these problems of access.  A 
recent meta-analysis showed that structured telephone support reduced heart failure-related 
hospitalisations [6]. However, the studies included in this meta-analysis did not focus on 
patients in rural and remote areas. Thus, the question of its efficacy for rural and remote 
patients remains unanswered. 
 
  
A
cc
ep
te
d 
A
rt
ic
le
© 2012 Blackwell Publishing Ltd 
The aim of the present study was therefore to determine whether an automated telephone 
support system would improve quality-of-life and reduce death and hospital admissions for 
rural and remote heart failure patients. 
 
Methods 
The study was approved in 2003 by the Monash University Human Research Ethics 
committee (no. 2003/306).  All patients provided written informed consent. Recruitment 
began in 2003 with first patient randomized in 2004. 
 
Patient Population 
Patients were enrolled based on their general practitioners’ location in rural and remote areas 
of Australia.  We later also included general practitioners in outer metropolitan areas whose 
patients had limited or no access to heart failure management programs run by major 
metropolitan hospital centres.   
 
The patients were required to have New York Heart Association (NYHA) Class II-IV heart 
failure, left ventricular ejection fraction <40% on echocardiogram or echocardiographic 
features of diastolic dysfunction with impaired ventricular relaxation reported with no other 
diagnostic explanation for CHF-type symptoms such as chronic obstructive airways disease 
or bronchial asthma. Patients had to have a recent primary hospital discharge diagnosis of 
heart failure within the previous five years. They also had to have touchtone telephone access 
and the ability to operate this system [7].   
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Study Design 
The study involved cluster randomisation at the level of the general practitioner (1:1, usual 
care, usual care plus intervention, stratified by rural, remote and outer metropolitan area 
(RRMA) classification).  This was to minimize contamination across the two interventions to 
which patients were randomised.  Usual care (UC) involved standard general practice 
management of heart failure. Study personnel provided general practitioners with the 
National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Heart 
Failure Management Guidelines (2001) [8] and a diuretic treatment algorithm which could be 
utilised to manage patients’ volume status. Their patients received an individualised patient 
diary but no other literature. As part of the UC group no visits were prescheduled with their 
general practitioner and patients were advised to see their general practitioner when they 
needed to. 
 
In addition to UC, the usual care plus intervention (UC+I) group received ongoing support by 
touchtone telephone using the TeleWatch™ system.  The TeleWatch™ system is a 
telephone-based automated telemedicine system developed by Johns Hopkins Biomedical 
Engineering in conjunction with their clinical heart failure group. 
 
This telemedicine system was required to be dialled into by the patient on an at least a 
monthly basis at which time questions were asked with regard to: heart failure clinical status, 
medical management of their condition and social questions relevant to their heart failure 
status.  Specific questions are summarised in Table 1.  Alerts were set up within the 
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Telewatch system alerting the CHAT nurse via the Patient Watch Screen to follow up 
patients that reported prespecified signs or symptoms warranting intervention.  
 
In addition to monthly phone calls, patients were able at any time to dial into this automated 
system and receive advice about management of their heart failure symptoms or be directed 
to either general practitioner follow-up or presentation to the Emergency Department of their 
local hospital, based on automated responses generated by patient interaction. Furthermore, 
patients could at any time elect to speak to a heart failure specialist nurse who was available 
throughout the study program. If the patient was unable to access their general practitioner, 
the heart failure nurses could implement a study-specific diuretic algorithm if needed. The 
patients were advised to see their general practitioner or to attend the Emergency Department 
as soon as possible. Diuretics were the only medications that were titrated by the heart failure 
specialist nurses. 
 
The heart failure specialist nurses consisted of four core staff with between 5-25 years of 
cardiac nursing experience. Each of the nurses received training in the TeleWatchTM system 
in addition to bi-annual heart failure seminars.  
 
Patients in the UC+I were also provided with an action plan that outlined how to detect 
clinical deterioration and when and how to access emergency medical care. They also 
received a patient information resource about heart failure, regular newsletters and an 
individualised patient diary to record all clinical information including hospital and general 
practitioner visits.  
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General practitioners randomised to this group also received a copy the National Heart 
Foundation of Australia/Cardiac Society of Australia and New Zealand Heart Failure 
Management Guidelines (2001) [8], a quick reference guide of this information for their 
desktop, heart failure specific educational material and regular study newsletters. 
 
All patients regardless of treatment allocation were followed up by an independent reviewer, 
blinded to treatment allocation, and asked to complete a telephone survey at baseline, six and 
12 months. The survey included questions relating to quality of life (Minnesota Living with 
Heart Failure questionnaire), NYHA class, global health assessment [8] and EQ-5D 
EuroQOL and questions regarding utilization of health services. 
 
Study End-Points 
The primary end-point of the study was the Packer clinical composite score [9] at 12 months 
comprising the following elements: 
• Death 
• Hospital admission for heart failure 
• Withdrawal from study due to worsening heart failure 
• Seven-point global health assessment questionnaire 8 with regard to overall wellbeing 
in comparison to baseline.   
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Patients were considered as improved, worse or unchanged depending on these responses as 
per the original Packer scoring system [10]. 
 
Secondary end-points comprised all-cause death and all-cause hospitalisation as well as heart 
failure-related death, and heart failure-specific hospitalisation.  All hospitalisation data were 
adjudicated by three cardiologists (blinded to randomisation allocation) to determine if the 
hospitalisations were related to heart failure. Utilisation of life-saving therapies comprising 
use and dose of an ACE inhibitor was recorded in the UC+I group at 12 months. 
 
A sub-study of patients had N-terminal-proBNP plasma levels measured at baseline, six 
months and 12 months.   
 
Sample size 
Sample size was based on the Packer composite scale as the primary outcome.  It was 
assumed that at the end of 12 months follow up of the UC patients would comprise 25% 
improved, 50% no change, 25% worsened.  A shift of approximately 10% in the UC+I group 
(to a distribution of 36%, 48%, 16%) corresponding to an odds ratio of 1.65 in a proportional 
odds model was desired to be detected with 80% power.  With patients individually 
randomised this would have required 222 patients per arm. With an average of three patients 
per practice in a cluster-randomised design, an estimated intra-practice correlation of 0.10, 
and applying the design effect for interval-scaled measures, the approximate sample size 
inflation factor was 20%, leading to a total sample size of 534 patients from 178 practices.  
Due to slower than expected recruitment the sample-size calculation was revisited after 
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approximately 400 patients had been recruited.  Calculations indicated that a shift of 
approximately 11% (to 37%, 47%, 16% in the UC+I arm) corresponding to an odds ratio of 
1.78 was able to be detected with 80% with this sample size.  Since this represented only a 
very minor difference from the original target of a 10% shift, the trial was terminated at that 
point in recruitment.  
 
Statistical Analysis 
Intention-to-treat analyses were performed for all endpoints.  All analyses were adjusted for 
clustering at practice level using a robust variance estimator. The 3-point scale of the Packer 
Composite Score was analysed with a proportional odds model which assesses the odds of a 
better outcome in UC+I patients compared to UC.  Assessment of proportionality of odds was 
performed using Wald tests [11]. Time-to-event endpoints were displayed with Kaplan-Meier 
curves and hazard ratios estimated using Cox proportional hazards regression, first 
unadjusted, then adjusted for covariates as above.  All analyses were performed using Stata 
version 10. 
 
 
Results 
Characteristics of general practitioners 
One hundred and forty-three rural, remote and outer metropolitan general practitioners from 
127 individual general practitioner clusters were recruited into the CHAT study (Figure 1).  
Several general practitioners failed to recruit patients (n=170). However, there were no 
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significant differences in characteristics of general practitioners between those that recruited 
patients and those that did not. Barriers to patient recruitment were outside the scope of this 
study. 
 
In the UC group, 23 of 74 general practitioners were the sole general practitioner in their 
practice compared to 22 of 69 general practitioners in the UC+I. The number of general 
practitioners in the practice ranged from 1 to 12 general practitioners in both the UC and 
UC+I groups.  
 
Participation of general practitioners was obtained from all Australian States and Territories 
(Figure 2).The distribution of general practitioners between rural, remote and outer 
metropolitan areas was not significantly different between groups (Figure 3).  
 
Patient Characteristics 
Patients were well-matched at baseline for disease severity, co-morbidities, haemodynamic 
parameters and concomitant medications (Table 2). 
 
Resource utilisation  
Patients in the UC group visited their general practitioner more frequently compared to UC+I 
(12.55 GP visits/patient (UC) versus 5.85 GP visits/patient (UC+I)). Overall, more than 65% 
of patients adhered with the TeleWatchTM protocol (65.8%, 95% confidence interval 0.54-0.75, 
p<0.001) [12] and made an average of 24 unscheduled calls/patient into the TeleWatchTM system.  
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Primary End-Point 
Results related to the Packer clinical composite score are shown in Figure 4.  There was no 
difference in the percent of patients who were worse, unchanged or better between the UC 
and UC+I (proportional odds ratio = 1.01, p=0.98).  Adjustment for age, gender, practice 
region (RRMA) and baseline NYHA class resulted in minimal difference to this result 
(OR=1.02, p=0.91). 
 
In terms of the components of the Packer score: there were 16 deaths in UC compared to 17 
in UC+I; 35 of 204 heart failure-related hospitalisations in UC compared to 23 of 161 
patients in UC+I; 8 patients withdrew in UC due to worsening heart failure compared to 10 
patients in UC+I; and in UC  29 of 102 patients had an improvement in the global health 
questionnaire at 12 months compared to 32 of 90 patients in UC+I. 
 
All-Cause Death and All-Cause Hospitalisation 
One hundred and twenty-four of 209 UC and 86 of 170 UC+I patients reached the end-point 
of all-cause death or all-cause hospitalisation. This resulted in an unadjusted hazard ratio of 
0.75 (range 0.57 to 0.99, p=0.045) and an adjusted hazard ratio of 0.70 (range 0.53 to 0.92, 
p=0.011).  Kaplan-Meier plot of the timing of events in the UC and UC+I group is shown in 
Figure 5. There was no significant difference in all-cause death or all-cause hospitalisation 
according to general practitioner location in rural, remote or outer metropolitan areas. 
 
 
 
  
A
cc
ep
te
d 
A
rt
ic
le
© 2012 Blackwell Publishing Ltd 
All-Cause Hospitalisation 
One hundred and fourteen of 204 UC and 74 of 161 UC+I patients were hospitalised during 
the 12-months follow-up period of the trial.  This resulted in an unadjusted hazard ratio of 
0.71 (range 0.53 to 0.95, p=0.021) and an adjusted hazard ratio of 0.67 (range 0.50 to 0.89, 
p=0.006).  The Kaplan-Meier plot of these events is shown in Figure 6. 
 
Heart Failure Hospitalisation 
Thirty-five of 204 and 23 of 161 patients were hospitalised for heart failure.  This resulted in 
an unadjusted hazard ratio of 0.81 (0.44 to 1.38, p=0.43) and an adjusted hazard ratio of 0.78 
(0.45 to 1.33, p=0.36). 
 
All-Cause Death 
Sixteen patients among 209 in the UC group and 17 of the 170 UC+I group died during the 
study.  This resulted in an unadjusted hazard ratio of 1.3 (range 0.65 to 2.77, p=0.43) and 
adjusted hazard ratio of 1.36 (0.63 to 2.93, p=0.439). 
 
Prescribing of ACE Inhibitor Therapy 
Sixty one percent and 54% of patients were prescribed ACE inhibitors at baseline in the UC 
and UC+I groups, respectively.  Of the patients receiving ACE inhibitors at baseline, there 
was no significant difference between randomised groups in the percentage of patients 
prescribed maximal dose (8% of patients in UC compared to 7% of patients in UC+I). Fifty-
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five percent of UC+I patients were receiving these medications post-randomisation of which 
15% were prescribed maximum dose.  
 
Change in Plasma NT-proBNP 
Plasma NT-proBNP values (median and IQR) at baseline were 1053(370-2341) and 
1105.5(367.75-2572.5) for UC (n=203) and UC+I (n=176) groups respectively. At 12 months 
the NT-proBNP levels were 960(374-2007) and 1083(408.5-2182.5), for UC (n=123) and 
UC+I (n=117) groups respectively.   
 
Discussion 
This study found that an automated telephone support system provided to rural, remote and 
outer metropolitan heart failure patients resulted in no change in the Packer clinical 
composite score in comparison to usual care, the primary end-point.  It did, however, lead to 
a significant reduction in risk of the composite of all-cause death or hospitalisation, as well as 
all-cause hospitalisation alone.  Furthermore, there was a non-significant (approximately 
20%) reduction in risk of heart failure hospitalisation but no difference in all-cause mortality.  
There was also an increase in utilisation of general practitioners, with the control group 
visiting their general practitioner more than twice as often as the intervention group. This 
may be due to compliance (in 65%) with the automated telephone support system in the 
intervention group reducing the need for participants in the intervention group to visit their 
general practitioner. 
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Based on the favourable effects of the telephone-based intervention, primarily on 
hospitalisations this may represent a novel approach to healthcare delivery targeting rural and 
remote patients with chronic disease particularly those without access to multidisciplinary 
community-based care.   
 
Two recent studies found similar results to these particularly in the non-significant effect on 
all-cause mortality and heart-failure related hospitalisations. A recent study of 710 stable 
chronic heart failure patients investigated the efficacy of a physician-led telemedical 
management system [13]. Patients randomised to the telemedical management group used 
electronic devices for monitoring of the ECG, blood pressure and weight. All patients were 
followed for 2 years. The investigators found no significant difference in all-cause mortality, 
cardiovascular death or heart failure-related hospitalisations between the usual care and 
telemedical management groups [13]. They did not report  all-cause hospitalisations. In 
another controlled trial, the Tele-HF study [14] tested a structured telephone support system 
similar to that used in our study. They randomised 1653 patients who had been recently 
hospitalised with heart failure to undergo telemonitoring or usual care [14]. Their 
telemonitoring system was a telephone-based interactive voice system that collected 
information about symptoms and weight. All patients were followed up for six months. The 
study found no significant difference in all-cause mortality or hospitalisation, or heart failure-
related hospitalisations between the groups [14]. The major difference in this study was the 
length of follow-up as all patients in our study were followed up for 12 months which may 
account for our finding of a significant reduction in all-cause death or hospitalisation. Both of 
these studies have been published since previous meta-analyses of the efficacy of 
telemonitoring in heart failure patients. In light of these conflicting results with previous 
meta-analyses, further studies are clearly warranted. 
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Reduction in hospitalisation is a major benefit of any intervention in the management of the 
patient with chronic heart failure.  Requirement for hospitalisation may be considered a 
surrogate for progression of disease and/or ability of the patient to cope with an exacerbation 
of their condition.  Because hospitalisation represents over half of all healthcare costs 
associated with heart failure [15], reduction in this outcome can have a major impact on the 
public health burden of the condition. 
 
Limitations 
There were several limitations. Firstly, it is unclear why a corresponding reduction in 
mortality was not also observed with the usual care plus intervention group compared to 
those receiving usual care alone.  It may be that the intervention had insufficient power to 
impact on survival but could on hospitalisation, or that the study was under-powered to 
reliably address effects on this endpoint. In addition, the initial aim of the study was to 
determine the effect of an automated telephone support system in exclusively rural and 
remote patients. However, due to an insufficient number of general practitioners in these 
areas, general practitioners in outer metropolitan areas were subsequently recruited. It is also 
of interest that background use of ACE inhibitors was not increased in the intervention group. 
Therefore the improved outcomes in this group did not relate utilisation of this life-saving 
class of agent. Data on beta-blocker use following randomisation was not collected in this 
study, as the automated telephone support system was not set-up to collect such information. 
 
The automated telephone support system provides insight into the potential benefits of 
multidisciplinary care in patients with heart failure.  In particular, the ability to closely 
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interact with a healthcare professional with appropriate expertise may provide significant 
security to the patient, reduce anxiety and improve quality of life [12]. 
 
Based on the beneficial impact on hospitalisation in the present study of patients with chronic 
heart failure, automated telephone support may be considered for other chronic disease states 
where ongoing management is required and multidisciplinary approaches cannot be accessed 
by patients living in rural and remote regions.  Such disease states may include chronic 
arthritis, chronic obstructive pulmonary disease, diabetes mellitus and osteoporosis.   
 
In summary, we have found that an automated telephone support approach to the 
management of rural and remote patients with heart failure who have reduced access to 
management programs, impacts primarily and significantly on hospitalisation. This has 
attendant benefits to the individual patient and the healthcare system.  These findings support 
further evaluation to determine the cost-effectiveness of such an intervention as well as its 
potential for implementation across other chronic disease states. 
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Table 1: Telewatch questions 
Telewatch questions Patients’ response through Telewatch  
Social Questions 
On a scale of 1-8 how stressful is your life 
(1-no stress, while 8- high stress)  
Using the key pad on your phone enter a 
number 1 to 8 which most closely reflects the 
level of your stress today. 
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In the past week have you been feeling more 
depressed, hopeless or have a feeling of 
helplessness? 
Press 1 for YES, 2 for NO 
 
Did you smoke any cigarettes or cigars in the 
past day? 
Press 1 for YES, 2 for NO  
If yes: How many cigarettes did you smoke?  
You may respond at any time 
  1 = less than ½ pack 
  2 = ½ - 1 pack 
  3 = more than 1 pack 
 
 
How many alcoholic drinks, beers and 
glasses of wine did you drink yesterday 
Enter the total number of alcoholic drinks, 
beers and glasses of wine that you drank 
yesterday followed by the # (hash) sign. 
Did you exercise in the past day?   Press 1 for YES, 2 for NO.  If yes go to 
Exercise Module 
Medical Management Questions  
Since you last used the CHAT System did 
you miss a Doctor or Nurse 
appointment in the past week? 
Press 1 for YES, 2 for NO. If yes go to 
Appointment module 
In the past day, for any reason did you not Press 1 for YES, 2 for NO. If yes go to 
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take your medicines at the correct time 
or the correct dose? 
Medicine Adherence Module 
 
Were any of your medications or 
prescriptions changed in the past week?  
Press 1 for YES, 2 for NO 
Heart Failure Questions 
Did you measure the total amount of fluid 
that you drank yesterday?   
Press 1 for YES, 2 for NO 
If yes: How many litres of fluid did you drink 
yesterday  
Enter the number of litres of fluid you drank 
yesterday followed by the # (hash) symbol 
Are you taking any medicines, over the 
counter medications or natural 
supplements for arthritis? 
Press 1 for YES, 2 for NO. 
Are you more light headed than usual Press 1 for YES, 2 for NO. If yes go to 
Dehydration module 
 
Have you noticed your heart racing, skipping 
or slowing more than usual 
What was your weight? 
Press 1 for YES, 2 for NO. - If yes go to 
Arrhythmia Module  
Enter your weight in kilograms followed by 
the # symbol 
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Compared to last week are you more short of 
breath? 
 
Press 1 for YES and 2 for NO  
If yes go to Excess Body Fluid Module 
Compared to yesterday do you have more 
ankle, leg or tummy swelling? 
 
Press 1 for YES, 2 for NO.  If YES go to 
Excess Body Fluid Module 
Compared to last week is a new cough or 
night time shortness of breath 
interrupting your sleep or forcing you 
to sleep in a more upright position? 
Press 1 for YES, 2 for NO.  If YES go to 
Excess Body Fluid Module 
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Table 2: Patient characteristics 
 
 
Usual Care 
(n=217) 
Usual Care + 
Intervention 
(n=188) 
Age (years) 73 ± 11 73 ± 10 
Gender (% female) 36 38 
NYHA Class (II/III/IV) 60/37/3 58/34/9 
Systolic heart failure 68% (131/193) 52% (82/158) 
Diastolic heart failure (HFPSF) 30% (49/164) 17% (25/145) 
Ejection fraction (%) (mean±SD) 34.9±23.48 37.2±14.14 
Hypertension (%) 59 61 
Diabetes mellitus (%) 32 29 
Atrial fibrillation (%) 37 39 
Pacemaker (%) 15 9 
ICD (%) 6 3 
Systolic BP (mmHg) 122 ± 19 124 ± 19 
Diastolic BP (mmHg) 71 ± 11 71 ± 11 
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Heart rate (bpm) 72 ± 12 73 ± 12 
eGFR (mL/min/1.73m2) 63 ± 28 59 ± 22 
Baseline NT-proBNP (median [IQR]; 
pmol/L) 
1053 (370-2341) 1105.5 (367.75-2572.5) 
Medications 
ACE inhibitor (%) 61 54 
ARB (%) 25 25 
Both (%) 1 2 
Beta-blockers 
HF specific (%) 66 56 
Non-HF specific (%) 13 19 
Aldosterone antagonist (%) 28 24 
Diuretic (%) 76 84 
 
NYHA = New York Heart Association; ICD= internal cardiodefibrillator; eGFR = estimated 
glomerular filtration rate; NT-proBNP = N terminal pro-brain natriuretic peptide; bpm = 
beats per minute; IQR = interquartile range 
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Legend to Figures 
 
Figure 2: Clusters of participating general practitioners throughout Australia  
 
Figure 4: Packer clinical composite score 
This was measured at 12 months with last observation carried forward.  Assessment was 
made by ordinal logistic regression with proportional odds assumption.  Adjustment was by 
age, gender, practice region and NYHA class. 
 
Figure 5: All-cause death and all-cause hospitalisation 
Kaplan-Meier plot for all-cause death and hospitalization.   
 
Figure 6: All-cause hospitalisation 
Kaplan-Meier plot for all-cause hospitalization.   
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Figure 1 : flowchart of patient enrolment 
GPs sent an expression of interest 
form to participate in the study 
(n=1542) 
GP randomised into the study 
(N=313) 
GPs that did not return the 
expression of interest form 
16 patients 
ineligible 
217 patients enrolled 
74 GPs randomised to the 
usual care group   
69 GPs randomised to the 
intervention group   
204 patients recruited230 patients recruited 
188 patients enrolled
13 patients 
ineligible 
GPs failed to recruit patients 
(N=170)
143 GPs recruited patients for the 
study (127 clusters of GPs) 
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Figure 3: Distribution of general practitioner clusters 
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